The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characteristics.
Lauren C BylsmaRebecca DeanKimberly A LoweLaura SangaréDominik D AlexanderJon P FryzekPublished in: Cancer medicine (2019)
IRs occur in approximately 5% of mCRC patients treated with anti-EGFR therapies, and the incidence varies significantly by grade of severity and therapy type. Studies evaluating these outcomes should consider investigating survival outcomes by IR status to determine its prognostic relevance.
Keyphrases
- epidermal growth factor receptor
- monoclonal antibody
- tyrosine kinase
- metastatic colorectal cancer
- end stage renal disease
- advanced non small cell lung cancer
- risk factors
- newly diagnosed
- chronic kidney disease
- small cell lung cancer
- ejection fraction
- low dose
- prognostic factors
- peritoneal dialysis
- type diabetes
- case report
- patient reported outcomes
- drug induced
- weight loss
- mesenchymal stem cells
- replacement therapy